These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1054 related items for PubMed ID: 27454922

  • 1. Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.
    Wang L, Benzinger TL, Su Y, Christensen J, Friedrichsen K, Aldea P, McConathy J, Cairns NJ, Fagan AM, Morris JC, Ances BM.
    JAMA Neurol; 2016 Sep 01; 73(9):1070-7. PubMed ID: 27454922
    [Abstract] [Full Text] [Related]

  • 2. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
    Leuzy A, Smith R, Cullen NC, Strandberg O, Vogel JW, Binette AP, Borroni E, Janelidze S, Ohlsson T, Jögi J, Ossenkoppele R, Palmqvist S, Mattsson-Carlgren N, Klein G, Stomrud E, Hansson O.
    JAMA Neurol; 2022 Feb 01; 79(2):149-158. PubMed ID: 34928318
    [Abstract] [Full Text] [Related]

  • 3. Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology.
    Gordon BA, Blazey T, Su Y, Fagan AM, Holtzman DM, Morris JC, Benzinger TL.
    JAMA Neurol; 2016 Oct 01; 73(10):1192-1200. PubMed ID: 27548756
    [Abstract] [Full Text] [Related]

  • 4. Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders.
    Ossenkoppele R, Rabinovici GD, Smith R, Cho H, Schöll M, Strandberg O, Palmqvist S, Mattsson N, Janelidze S, Santillo A, Ohlsson T, Jögi J, Tsai R, La Joie R, Kramer J, Boxer AL, Gorno-Tempini ML, Miller BL, Choi JY, Ryu YH, Lyoo CH, Hansson O.
    JAMA; 2018 Sep 18; 320(11):1151-1162. PubMed ID: 30326496
    [Abstract] [Full Text] [Related]

  • 5. Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders.
    Leuzy A, Smith R, Ossenkoppele R, Santillo A, Borroni E, Klein G, Ohlsson T, Jögi J, Palmqvist S, Mattsson-Carlgren N, Strandberg O, Stomrud E, Hansson O.
    JAMA Neurol; 2020 Aug 01; 77(8):955-965. PubMed ID: 32391858
    [Abstract] [Full Text] [Related]

  • 6. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
    Ossenkoppele R, Smith R, Mattsson-Carlgren N, Groot C, Leuzy A, Strandberg O, Palmqvist S, Olsson T, Jögi J, Stormrud E, Cho H, Ryu YH, Choi JY, Boxer AL, Gorno-Tempini ML, Miller BL, Soleimani-Meigooni D, Iaccarino L, La Joie R, Baker S, Borroni E, Klein G, Pontecorvo MJ, Devous MD, Jagust WJ, Lyoo CH, Rabinovici GD, Hansson O.
    JAMA Neurol; 2021 Aug 01; 78(8):961-971. PubMed ID: 34180956
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden.
    Buckley RF, Hanseeuw B, Schultz AP, Vannini P, Aghjayan SL, Properzi MJ, Jackson JD, Mormino EC, Rentz DM, Sperling RA, Johnson KA, Amariglio RE.
    JAMA Neurol; 2017 Dec 01; 74(12):1455-1463. PubMed ID: 28973551
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Associations Between Amyloid and Tau Pathology, and Connectome Alterations, in Alzheimer's Disease and Mild Cognitive Impairment.
    King-Robson J, Wilson H, Politis M, Alzheimer’s Disease Neuroimaging Initiative.
    J Alzheimers Dis; 2021 Dec 01; 82(2):541-560. PubMed ID: 34057079
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Associations Between Tau, β-Amyloid, and Cognition in Parkinson Disease.
    Winer JR, Maass A, Pressman P, Stiver J, Schonhaut DR, Baker SL, Kramer J, Rabinovici GD, Jagust WJ.
    JAMA Neurol; 2018 Feb 01; 75(2):227-235. PubMed ID: 29228071
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
    Schreiber S, Schreiber F, Lockhart SN, Horng A, Bejanin A, Landau SM, Jagust WJ, Alzheimer’s Disease Neuroimaging Initiative.
    JAMA Neurol; 2017 Jun 01; 74(6):650-659. PubMed ID: 28319241
    [Abstract] [Full Text] [Related]

  • 19. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K.
    JAMA Neurol; 2019 Jul 01; 76(7):791-799. PubMed ID: 31009028
    [Abstract] [Full Text] [Related]

  • 20. Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease.
    Xia C, Makaretz SJ, Caso C, McGinnis S, Gomperts SN, Sepulcre J, Gomez-Isla T, Hyman BT, Schultz A, Vasdev N, Johnson KA, Dickerson BC.
    JAMA Neurol; 2017 Apr 01; 74(4):427-436. PubMed ID: 28241163
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.